Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
2216-51-5
Molecular formula
C10H20O
Molecular weight
156.2652 g/mol
Drug class
Topical counterirritant and local cooling agentTRPM8 agonist
Mechanism of action
Activates cold-sensitive transient receptor potential melastatin-8 (TRPM8) channels in cutaneous sensory nerves, producing a cooling sensation. Counter-irritant and sensory-modulating effects can reduce perception of local pain or discomfort.
Indications / reported uses
Topical relief of headache with authorised cutaneous formulations.
Symptomatic relief of nasal congestion and common-cold symptoms with authorised nasal preparations.
Topical relief of minor muscle and joint pain in appropriate combination products.
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Levomenthol PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Levomenthol Permitted Daily Exposure (PDE) report (the Levomenthol PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Levomenthol Occupational Exposure Limit (OEL) report (the Levomenthol OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.